This page contains only findings drawn directly from published studies and official sources, with citations. No projections, interpretations, or unverified figures are included here — see the full note for analysis and recommendations.

The national target and its threshold

• India’s National Action Plan for Dog-Mediated Rabies Elimination (NAPRE), jointly launched by the Ministry of Fisheries, Animal Husbandry and Dairying and the Ministry of Health and Family Welfare (24 March 2023), commits India to zero human deaths from dog-mediated rabies by 2030 [1][2].

• Breaking rabies transmission in a dog population requires at least 70% of that population to carry protective antibodies at any given time [3].

• The WHO/OIE-defined threshold for a protective rabies antibody titre is ≥0.5 IU/mL [5].

What Indian field serosurveys have measured in vaccinated street dogs

• Bengaluru (BBMP, ATREE-linked study): Of 250 free-roaming dogs vaccinated with Raksharab under the municipal ABC-ARV programme, only 50% (RFFIT) / 50.4% (ELISA) carried a protective titre [6][7].

• Bengaluru (2023 follow-up, all 8 BBMP zones): 71% of sampled dogs showed adequate immune response by RFFIT overall; this fell to 53.7% in one zone (RR Nagar) [8][9].

• Chennai (Madras Veterinary College): Of 297 vaccinated owned dogs, only 40% carried a protective titre; among dogs vaccinated within the preceding year, protection was also only 40% [10][11].

• Mumbai: An ELISA serosurvey found 39.2% of street dogs carried protective antibody levels [12].

Head-to-head vaccine comparison trials (titre magnitude, same conditions)

• Bhutan field trial: Rabisin produced significantly higher day-28 titres than Raksharab — 3.83 IU/mL vs. 2.55 IU/mL (p = 0.004). Both cleared the 0.5 IU/mL threshold [13].

• Laboratory comparison of 30 dogs over 4 months: peak titre at 2 weeks was 2.53 IU/mL for Rabisin vs. 1.26 IU/mL for Nobivac Rabies — a two-fold difference in the same dogs [14].

Cold chain and thermostability

• A lyophilised rabies vaccine in current Indian use (Rabivax-S) requires 2–8°C storage and has a post-reconstitution shelf life of only 6 hours [18].

• Officials attributed a rabies death in Mani Majra (northern India) to suspected cold-chain failure in vaccine supply [19].

• A field trial in East Africa found a commercial canine rabies vaccine retained potency and produced equivalent seroconversion (85% in both arms) when stored in a low-cost passive cooling device under fluctuating ambient temperature, instead of a refrigerator [20][21].

• Experimental thermostable rabies vaccine platforms have shown no loss of immunogenicity after 3 months of storage at 50°C; an mRNA rabies vaccine candidate retained protective efficacy after exposure to 70°C [22][23].

Cost of the downstream burden

• India delivers an estimated 29 million post-exposure prophylaxis (PEP) courses annually; PEP already consumes roughly 83% of total rabies-control spending across Asia and Africa [24].

• India accounts for an estimated 33% of global rabies deaths [2].

Access, not just vaccine choice, limits coverage of free-roaming dogs

• A Goa field trial found oral bait handout (OBH) teams reached 35 dogs per person per day, versus 9 dogs per person per day for traditional catch-vaccinate-release netting [26][27].

• National-scale modelling estimated a two-week catch-vaccinate-release campaign would require ~1.1 million field staff to cover India’s free-roaming dog population, versus ~293,000 for an oral bait-based approach [16].

• Cost-optimisation modelling found that including oral rabies vaccination for free-roaming dogs remains the most cost-effective route to elimination even when bait costs up to 10x the price of a parenteral dose [24][28].

The core argument, stated plainly

India has committed, alongside the rest of the world, to end human deaths from dog-mediated rabies by 2030 under the National Action Plan for Dog-Mediated Rabies Elimination (NAPRE), launched jointly by the Ministry of Fisheries, Animal Husbandry and Dairying and the Ministry of Health and Family Welfare in March 2023 [1][2]. That plan rests on one epidemiological fact: at least 70% of a dog population must carry protective rabies antibodies at any given time to break transmission [3]. Everything else — surveillance, bite management, immunoglobulin supply — is downstream of that single number.

A saving of ₹10–20 per dose on a vaccine tender looks trivial against India’s estimated annual rabies burden of roughly 20,000 human deaths and $2.3 billion in economic losses [4]. But procurement built around lowest-landed-cost (the “L1” principle common to Government e-Marketplace and municipal tenders) treats all IP-1 compliant inactivated rabies vaccines as interchangeable commodities. Field serology from India’s own cities shows they are not. When a vaccine’s antibody response is weaker or shorter-lived, and it is used on a population — free-roaming street dogs — that is by definition almost impossible to recall for a booster, the “savings” are not savings at all. They are a transfer of cost from the municipal budget line to unvaccinated bite victims, post-exposure prophylaxis (PEP) wards, and, ultimately, the 2030 target itself.

1. What Indian field data actually shows about vaccine performance in street dogs

The theoretical minimum for rabies protection, set by WHO and the World Organisation for Animal Health (WOAH/OIE), is a virus-neutralising antibody (VNA) titre of ≥0.5 IU/mL [5]. That threshold is not controversial. What is striking is how often India’s own mass dog vaccination (MDV) programmes fall short of it — not because the vaccines fail bench-scale potency tests, but because of what happens to them between the manufacturer and the dog.

Bengaluru (BBMP) — the study behind the “ATREE” reference. Researchers from the KVAFSU-CVA Rabies Diagnostic Laboratory, working with the Ashoka Trust for Research in Ecology and the Environment (ATREE) on population data collection, sampled 250 free-roaming, ear-notched dogs that had been vaccinated with the Raksharab vaccine supplied by the Bruhat Bengaluru Mahanagara Palike (BBMP) under its Animal Birth Control–Anti-Rabies Vaccination (ABC-ARV) programme. Only 125 of the 250 dogs — exactly 50% — carried a protective titre (≥0.5 IU/mL) by the RFFIT gold-standard test; an in-house ELISA put satisfactory seroconversion at 50.4% [6][7]. A related, larger 2023 follow-up across all eight BBMP zones, after the city rolled out a more systematic mass dog vaccination campaign, found adequacy of response at 71% by RFFIT — still short of the 70% herd-immunity floor in several zones, and as low as 53.7% in one (RR Nagar) [8][9].

Chennai (Madras Veterinary College). A cross-sectional study of 297 vaccinated owned dogs found only 40% carried a protective titre overall, and — more tellingly — only 40% of dogs vaccinated within the preceding year were still protected. The authors were explicit about what this implies: “This high percentage of apparent non-responders is a cause of concern of administration, distribution, storage, potency and quality management of vaccines in India” [10][11].

Mumbai. An ELISA serosurvey of street and pet dogs found just 39.2% of street dogs carried protective antibody levels, with titres declining rapidly after the immediate post-vaccination window [12].

Read together, these are not isolated anomalies — they are a pattern, replicated across three of India’s largest, best-resourced municipal rabies programmes. If Bengaluru, Chennai, and Mumbai — with veterinary colleges, NGOs like Mission Rabies and Worldwide Veterinary Service embedded in their programmes, and comparatively strong civic capacity — are struggling to sustain herd immunity, the picture in smaller municipal corporations and panchayats, with weaker cold-chain infrastructure and no serosurveillance at all, is unlikely to be better.

2. The vaccine itself is one variable — and the comparative trials show it is not a neutral one

None of this is proof that any single low-cost vaccine is defective. IP-1/OIE-compliant vaccines pass potency testing at release. The issue is the margin of immune response they generate in field conditions, and how fast that margin decays — which determines whether a dog is still protected 10, 20, or 30 months after a campaign that, realistically, will not reach it again for a year or more.

Head-to-head comparative titre studies from the region are informative here:

Study	Vaccines compared	Result
Bhutan field trial, puppies & adults, day-28 titres [13]	Rabisin (Merial) vs. Raksharab (Indian Immunologicals)	Both cleared the 0.5 IU/mL WHO/OIE threshold, but Rabisin produced significantly higher mean titres by day 28: 3.83 IU/mL vs. 2.55 IU/mL (p=0.004)
Laboratory comparison, 30 dogs, titres over 4 months [14]	Rabisin vs. Nobivac Rabies	Peak titre at 2 weeks: 2.53 IU/mL (Rabisin) vs. 1.26 IU/mL (Nobivac) — a two-fold difference in the same dogs under the same conditions
Post-exposure challenge trial, 40 dogs [15]	Nobivac Rabies vs. Rabisin	Both fully protective against live-virus challenge, confirming that WHO/OIE-threshold vaccines can perform equivalently when correctly stored and administered

The lesson is not “brand X is bad.” It is that titre magnitude and persistence vary meaningfully even among fully licensed, potency-compliant vaccines, and that a procurement system that scores only on landed cost per dose has no mechanism to capture this variable at all. A vaccine that clears the bar by a comfortable margin on day 28 gives a municipal programme a buffer against the heat, handling, and delayed-revaccination realities of a street-dog campaign. A vaccine that clears the bar narrowly does not.

3. Why “just revaccinate more often” does not work for free-roaming dogs

For an owned pet, a shorter duration of immunity is an inconvenience — a reminder on the vet’s calendar. For a free-roaming street dog, it is close to a structural failure, because the entire cost of MDV is in the catching, not the injecting:

• A dog caught, netted, and vaccinated today may not be catchable again for 12–18 months. Recapture requires the same net teams, same fuel, same person-days as the first pass — there is no “quick booster.”

• India’s own operational research quantifies this: a national two-week catch-vaccinate-release (CVR) campaign is estimated to require roughly 1.1 million field staff to cover the country’s free-roaming dog population, against roughly 293,000 for an oral bait-based approach [16] — CVR is already the most labour- and cost-intensive delivery method in use, before any question of revaccination frequency is added.

• The Bengaluru and Chennai serosurveys are point-in-time snapshots, not duration-of-immunity studies — they were not designed to measure how many months or years a titre persists. What they do show is that a large share of dogs vaccinated within the past year, in real municipal programmes, are already below the protective threshold at the time they were sampled [8][9][10][11]. Whatever the exact duration curve turns out to be, that gap is happening well inside a single campaign cycle — and it is invisible without serosurveillance, because there is almost no routine post-vaccination testing built into Indian municipal contracts.

This is precisely why the NAPRE framework calls for at least 70% sustained coverage, not a one-time vaccination count [3]. A procurement decision that shaves the antibody margin or duration on a vaccine used exclusively on a hard-to-recapture population is optimising the wrong variable.

4. India’s heat is not a footnote — it is a second, compounding failure mode

Rabies vaccines are cold-chain-dependent. Standard requirements call for continuous 2–8°C storage from manufacture to administration [17], and India’s own pharmaceutical cold-chain literature acknowledges that “even within these systems, vaccines remain vulnerable to temperature excursions” that erode potency before the vial is even opened [17]. A modern lyophilised rabies vaccine used in India, Rabivax-S, has a post-reconstitution shelf life of just six hours under refrigeration [18] — a demanding window for a field vaccination camp operating out of a van in 40°C summer heat, often without reliable power at the point of use.

The consequences are not hypothetical. A widely reported case from Mani Majra in northern India — a six-year-old girl who died of rabies despite receiving post-exposure treatment — was attributed by health officials to suspected cold-chain failure in the vaccine supply [19]. That case involved human PEP, but the underlying vulnerability — thermolabile vaccine, weak last-mile cold chain, high ambient temperature — applies with equal or greater force to veterinary field campaigns, which typically have far less rigorous storage discipline than a hospital pharmacy.

There is a genuine silver lining here, and it points toward the innovation India should be funding rather than the corner it should be cutting. Field trials in East Africa found that a leading commercial canine rabies vaccine retained full potency and produced equivalent seroconversion (85% in both arms) after storage not in a refrigerator but in a low-cost passive cooling device under fluctuating ambient conditions [20][21] — evidence that thermostable or thermotolerant formulations can meaningfully de-risk last-mile delivery in exactly the conditions Indian field teams operate in. Next-generation candidates go further: experimental thermostable rabies vaccine platforms have shown no loss of immunogenicity after three months of storage at 50°C [22], and an mRNA rabies vaccine candidate has retained protective efficacy after exposure to temperatures up to 70°C [23]. None of this is standard Indian procurement practice today — but it is where a serious 2030 strategy should be steering vendor qualification criteria and R&D investment, rather than treating every compliant vaccine as identical on a spreadsheet.

5. What is actually being lost when procurement optimises for L1 alone

It is worth being precise about the chain of loss, because “cheaper vaccine” sounds like a saving until each downstream link is priced in:

1. Under-immunity is invisible until it isn’t. No municipal ABC-ARV contract in India routinely includes post-vaccination serosurveillance (RFFIT or ELISA) as a condition of payment. The Bengaluru and Chennai studies above exist because researchers went and checked — not because the programme design checks itself. A city can report “95% of the target dog population vaccinated” and still be nowhere near 70% protected, and have no way of knowing it.

2. Re-infection risk compounds with time. A street dog with waning titres re-enters the susceptible pool while still being counted, on paper, as “covered” — silently degrading herd immunity mid-cycle.

3. PEP absorbs the failure. India already delivers an estimated 29 million post-exposure prophylaxis courses a year, and PEP already consumes roughly 83% of total rabies-control spending across Asia and Africa [24]. Every dog that should have been immune and was not pushes more bite victims into that PEP pipeline — a far larger recurring cost than the per-dose saving that put them there.

4. Human deaths, and the ones that erode public trust. Rabies is 100% fatal once symptomatic and 100% preventable — the gap between those two facts is entirely a program-execution gap. A death attributable to an unvaccinated (or under-vaccinated-but-“counted”) dog does more than register as one more statistic in India’s 33%-of-global-rabies-deaths burden [2]; it corrodes public confidence in ABC-ARV programmes generally, feeding the narrative — already politically live in several Indian cities — that street-dog vaccination doesn’t work and dogs should simply be removed rather than managed. Cutting corners on vaccine quality is, in that sense, a direct threat to the political sustainability of the ABC model itself.

5. Time lost against a fixed deadline. 2030 is not a floating target. Every cycle spent vaccinating with a narrower immunological margin, undetected, is a cycle in which the national coverage curve looks better on paper than it is on the ground — and the gap only becomes visible in outbreak data, years later, when it is expensive to correct.

6. The innovation India should be racing toward: oral rabies vaccination

The single largest constraint on Indian MDV is not vaccine choice but access — a majority of India’s free-roaming dogs cannot be reliably caught for injection at all. Oral rabies vaccination (ORV), delivered via bait, has been used to eliminate rabies in wildlife reservoirs across Europe and North America since 1978 [25], and a growing evidence base argues it is now ready for free-roaming dog populations in endemic countries:

• A Goa “oral bait handout” (OBH) proof-of-concept, run by Mission Rabies, found field teams could reach 35 dogs per person per day via OBH versus 9 dogs per person per day via traditional catch-vaccinate-release netting [26][27] — a nearly four-fold gain in the single scarcest resource in Indian MDV: trained field staff.

• Formal cost-optimisation modelling of a national Indian vaccination strategy found that including oral bait vaccination for free-roaming dogs remains the most cost-effective route to elimination even when the bait costs up to ten times the price of a parenteral dose — because it converts unreachable dogs into reachable ones [28].

• WHO-recommended third-generation oral strains (SAG2, SPBN GASGAS, ONRAB) have established safety and immunogenicity profiles in international field trials, including specifically in Indian street dogs [29][30][31], and a dedicated non-meat bait formulation has been developed and tested for cultural and religious acceptability in Goa [32] — addressing a concern specific to the Indian context.

There is also an active citizen-led push on this front: a public petition campaigning for the introduction of oral rabies vaccination in India is live at change.org, reflecting that this is not only a technical recommendation but one with public constituency behind it.

ORV should not be framed as a replacement for parenteral MDV, but as the complementary tool that finally closes the access gap the current model cannot solve through injection alone — and it deserves a funded pilot-to-scale pathway from AHD and NCDC now, not after 2030 slips.

7. What this note is asking municipal and AHD administrators to do

None of the above is an argument to ignore cost. Public procurement law and fiscal prudence are real constraints, and any recommendation that pretends otherwise will be — correctly — ignored. The ask is narrower and more actionable:

1. Replace pure-L1 evaluation with Quality-and-Cost-Based Selection (QCBS) for rabies vaccine tenders, weighting technical criteria — demonstrated post-vaccination titre data, thermostability certification, cold-chain compliance track record, and independent field-performance evidence — alongside price, the way many high-value technical procurements already are, rather than in a strict cost-only ranking.

2. Make post-vaccination serosurveillance a funded, mandatory line item in every municipal MDV/ABC-ARV contract, not an academic afterthought. The Bengaluru and Chennai data above should not be the exception; they should be the routine monitoring baseline for every city running an MDV programme.

3. Set minimum titre-persistence benchmarks, not just release-potency compliance, as a qualification criterion — requiring vendors to submit field-durability data, not only cold-storage bench-test certificates.

4. Audit and invest in last-mile cold chain for veterinary vaccination camps specifically, treating the six-hour reconstituted shelf-life constraint of current lyophilised vaccines as an operational planning input, not a footnote.

5. Fund a phased oral rabies vaccine pilot in two or three high-density, low-catchability urban wards, building on the Goa evidence base, with NCDC/AHD co-ownership so lessons feed directly into the NAPRE 2030 monitoring framework.

6. Move toward multi-year, performance-linked vaccine contracts rather than annual lowest-bid re-tendering — this both reduces the perverse annual incentive to shave price at the margin and gives vendors of higher-titre, more thermostable vaccines a viable route to compete on total value rather than losing automatically on sticker price.

The case in one sentence

India is 100% capable of eliminating dog-mediated human rabies by 2030 — the biology and the tools already exist — but a procurement default that treats a ₹10–20 per-dose saving as a win, on a vaccine given to an animal population that is nearly impossible to recall for a booster, is quietly spending down the very herd immunity the 2030 target depends on; the fix is not a large budget increase, but a smarter definition of what “value for money” means when the product is immunity, not just a vial. This IS: Life or Death.

References

1. Ministry of Fisheries, Animal Husbandry and Dairying / Ministry of Health and Family Welfare, “National Action Plan for Dog Mediated Rabies Elimination (NAPRE) from India by 2030,” launched 24 March 2023. Press Information Bureau: https://www.pib.gov.in/PressReleasePage.aspx?PRID=1758964

2. TeamLease RegTech summary of NAPRE: https://www.teamleaseregtech.com/updates/article/22484/national-action-plan-for-dog-mediated-rabies-elimination-napre/

3. “Assessment of Immune Responses to Rabies Vaccination in Free-Ranging Dogs in Bengaluru, India,” Vaccines2023, 11(5), 888. https://www.mdpi.com/2076-393X/11/5/888

4. “Review of Oral Rabies Vaccination of Dogs and Its Application in India,” Viruses 2022, 14(1), 155. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777998/

5. Comparative rabies vaccine studies cite WHO/OIE 0.5 IU/mL threshold — see refs 6, 13, 14 below. 6–7. “A Comparative Evaluation of the Estimation of Rabies Virus Antibodies among Free-Roaming, Vaccinated Dogs in Bengaluru, India,” PMC8950950. https://pmc.ncbi.nlm.nih.gov/articles/PMC8950950/ 8–9. “Assessment of Immune Responses to Rabies Vaccination in Free-Ranging Dogs in Bengaluru, India,” PMC10224170 / Vaccines2023, 11, 888. https://pmc.ncbi.nlm.nih.gov/articles/PMC10224170/ 10–11. “Investigation of protective level of rabies antibodies in vaccinated dogs in Chennai, India,” Vet Rec Open, PMC8110021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110021/

6. “Serosurveillance of rabies antibodies in dogs in Mumbai region by using indirect ELISA.” https://www.sciencedirect.com/science/article/abs/pii/S0147957121000473

7. “Comparison of Antibody Responses after Vaccination with Two Inactivated Rabies Vaccines in Dogs in [Bhutan].” https://www.academia.edu/44364723/

8. “Comparison of antibody responses after vaccination with two inactivated rabies vaccines” (Rabisin vs Nobivac, 4-month titre study). https://www.researchgate.net/publication/23223500

9. “Post-exposure prophylaxis (PEP) of rabies-infected Indian street dogs.” https://www.sciencedirect.com/science/article/abs/pii/S0264410X0801308X

10. “The safety and efficacy of the oral rabies vaccine SAG2 in Indian stray dogs” / “Oral bait handout as a method to access roaming dogs for rabies vaccination in Goa, India.” https://www.sciencedirect.com/science/article/pii/S2590136219300166

11. “Thermostability of Vaccines in the Indian Context: A Review of Progress and Perspectives,” IJSRT Journal. https://www.ijsrtjournal.com/article/Thermostability+of+Vaccines+in+the+Indian+Context+A+Review+of+Progress+and+Perspectives

12. “Superior immune responses from thermostable, single-administration rabies vaccines prepared using atomic layer deposition,” PMC12642940 (cites Rabivax-S 2–8°C, 6-hour post-reconstitution shelf life). https://pmc.ncbi.nlm.nih.gov/articles/PMC12642940/

13. “Cold Chain Failure Suspected in Rabies Death,” VBI Vaccines, on the Mani Majra case. https://www.vbivaccines.com/thermostable-platform/rabies-vaccine-cold-chain-failure/ 20–21. “Investigating the Efficacy of a Canine Rabies Vaccine Following Storage Outside of the Cold-Chain in a Passive Cooling Device,” Front. Vet. Sci. 2021, PMC8511528. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511528/

14. “Superior immune responses from thermostable, single-administration rabies vaccines prepared using atomic layer deposition,” PMC12642940 (50°C, 3-month stability). https://pmc.ncbi.nlm.nih.gov/articles/PMC12642940/

15. “A thermostable messenger RNA based vaccine against rabies,” PLOS NTD 2017. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006108

16. “Optimizing rabies vaccination of dogs in India,” medRxiv 2023. https://www.medrxiv.org/content/10.1101/2023.04.10.23288318v1.full 25–32. Oral rabies vaccine India evidence base: “Review of Oral Rabies Vaccination of Dogs and Its Application in India” (PMC8777998); “Oral bait handout as a method to access roaming dogs for rabies vaccination in Goa, India” (ScienceDirect S2590136219300166); “Development of a Non-Meat-Based, Mass Producible and Effective Bait for Oral Vaccination of Dogs against Rabies in Goa State, India” (PMC6789727); “Immunogenicity of the Oral Rabies Vaccine Strain SPBN GASGAS in Dogs Under Field Settings in Namibia” (PMC8573107); “Optimizing rabies vaccination of dogs in India,” medRxiv 2023.

Public petition referenced: change.org/OralRabiesVaccine (citizen advocacy campaign for ORV introduction in India — cited as evidence of public constituency, not as a research source).

The False Economy of the Cheapest ARV: GoI, too much at stake; fix this at the root, and now

Table of Contents

The False Economy of the Cheapest Vaccine: Why India’s L1 Tender System Is Quietly Undermining Rabies Elimination by 2030

Executive Summary — Verified Facts